Zotarelli-Filho Idiberto José, Mogharbel Bassam Felipe, Irioda Ana Carolina, Stricker Priscila Elias Ferreira, de Oliveira Nathalia Barth, Saçaki Claudia Sayuri, Perussolo Maiara Carolina, da Rosa Nádia Nascimento, Lührs Larissa, Dziedzic Dilcele Silva Moreira, Vaz Rogério Saad, de Carvalho Katherine Athayde Teixeira
Advanced Therapy and Cellular Biotechnology in Regenerative Medicine Department, The Pelé Pequeno Príncipe Research Institute & Pequeno Príncipe Faculties, Curitiba 80240-020, Brazil.
Faculty of Medicine of São José do Rio Preto, FACERES., São José do Rio Preto, São Paulo 15090-305, Brazil.
Biomedicines. 2023 Apr 7;11(4):1113. doi: 10.3390/biomedicines11041113.
Identifying target microRNAs (miRNAs) might serve as a basis for developing advanced therapies for Parkinson's disease (PD) and Alzheimer's disease. This review aims to identify the main therapeutic targets of miRNAs that can potentially act in Parkinson's and Alzheimer's diseases. The publication research was conducted from May 2021 to March 2022, selected from Scopus, PubMed, Embase, OVID, Science Direct, LILACS, and EBSCO. A total of 25 studies were selected from 1549 studies evaluated. The total number of miRNAs as therapeutic targets evidenced was 90 for AD and 54 for PD. An average detection accuracy of above 84% for the miRNAs was observed in the selected studies of AD and PD. The major signatures were miR-26b-5p, miR-615-3p, miR-4722-5p, miR23a-3p, and miR-27b-3p for AD and miR-374a-5p for PD. Six miRNAs of intersection were found between AD and PD. This article identified the main microRNAs as selective biomarkers for diagnosing PD and AD and therapeutic targets through a systematic review and meta-analysis. This article can act as a microRNA guideline for laboratory research and pharmaceutical industries for treating Alzheimer's and Parkinson's diseases and offers the opportunity to evaluate therapeutic interventions earlier in the disease process.
识别靶微小RNA（miRNA）可能为开发帕金森病（PD）和阿尔茨海默病的先进疗法奠定基础。本综述旨在确定可能在帕金森病和阿尔茨海默病中发挥作用的miRNA的主要治疗靶点。文献研究于2021年5月至2022年3月进行，选自Scopus、PubMed、Embase、OVID、Science Direct、LILACS和EBSCO。从1549项评估研究中总共筛选出25项研究。已证实作为治疗靶点的miRNA总数，阿尔茨海默病为90个，帕金森病为54个。在所选的阿尔茨海默病和帕金森病研究中，观察到miRNA的平均检测准确率高于84%。阿尔茨海默病的主要特征性miRNA为miR-26b-5p、miR-615-3p、miR-4722-5p、miR23a-3p和miR-27b-3p，帕金森病为miR-374a-5p。在阿尔茨海默病和帕金森病之间发现了6个交叉的miRNA。本文通过系统综述和荟萃分析，确定了主要的微小RNA作为诊断帕金森病和阿尔茨海默病的选择性生物标志物以及治疗靶点。本文可为实验室研究和制药行业治疗阿尔茨海默病和帕金森病提供微小RNA指导原则，并提供在疾病进程中更早评估治疗干预措施的机会。
